Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women

被引:44
作者
Harichand-Herdt, Seema [1 ]
Ramalingam, Suresh S. [1 ]
机构
[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
关键词
SEX-ASSOCIATED DIFFERENCES; PROGNOSTIC-FACTORS; ESTROGEN-RECEPTOR; FEMALE-PATIENTS; PHASE-III; SURVIVAL; GEFITINIB; EPIDEMIOLOGY; CHEMOTHERAPY; PLUS;
D O I
10.1053/j.seminoncol.2009.10.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the leading cause of cancer deaths in the United States. In recent years the incidence of lung cancer in men has been declining, while in women it has been increasing. A number of population-based studies have demonstrated gender-based differences in clinical and pathologic factors, as well as in survival related to lung cancer. Disparities in age, smoking practices, and histological subtypes are among the differences that have been identified. Gender disparity also has been observed in outcomes, with improved survival observed for women in a number of clinical trials. This article reviews the gender-related differences in clinical and pathologic factors and outcomes of patients with lung cancer observed in population-based studies and clinical trials. Semin Oncol 36:572-580 (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:572 / 580
页数:9
相关论文
共 52 条
[1]  
Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226
[2]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[3]  
[Anonymous], INT J CANC
[4]   Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender [J].
Belani, C ;
von Pawel, J ;
Pluzanska, A ;
Gorbounova, V ;
Kaukel, E ;
Mattson, K ;
Ramlau, R ;
Fidias, P ;
Millward, M ;
Fossella, F .
LUNG CANCER, 2005, 49 :S235-S236
[5]  
Brahmer JR, 2007, J CLIN ONCOL, V25
[6]   Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men [J].
Cerfolio, Robert James ;
Bryant, Ayesha S. ;
Scott, Ethan ;
Sharma, Manisha ;
Robert, Francisco ;
Spencer, Sharon A. ;
Garver, Robert I. .
CHEST, 2006, 130 (06) :1796-1802
[7]   Gender difference in survival of resected non-small cell lung cancer: Histology-related phenomenon? [J].
Chang, Jee Won ;
Asamura, Hisao ;
Kawachi, Riken ;
Watanabe, Shun-ichi .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (04) :807-812
[8]   Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib [J].
Clark, Gary M. .
MOLECULAR ONCOLOGY, 2008, 1 (04) :406-412
[9]  
Danenberg K, 2004, J CLIN ONCOL, V22, p619S
[10]  
EBRIGHT MI, 2008, ANN THORAC SURG, V85, P216